Exa-cel earned its second FDA approval. The one-time therapy, which has a list price of $2.2 million in the United States, should be available for patients early this year.
Patients with severe sickle cell disease could soon be freed from vaso-occlusive crises after receiving an infusion of exa-cel, the first gene-editing therapy to use CRISPR technology.
Stopping metformin was linked to an increased risk for dementia diagnosis in a large cohort of adults with T2D, providing more evidence of the drug’s potential neuroprotective effects.